Alloy Pricing History and Trajectory: What Women Pay for Menopause HRT in 2024

What Alloy Actually Charges: A Pricing Timeline

Alloy launched in 2019 with subscription pricing designed to undercut traditional OB/GYN cash-pay visits. The founding premise was simple: women spend years and thousands of dollars getting a menopause diagnosis, then pay cash for branded HRT. Alloy aimed to compress that into one monthly fee.

Launch Pricing (2019 to 2021)

At launch, Alloy advertised an all-in subscription of approximately $49/month. That figure covered an initial async clinician consultation, a prescription for a standard low-dose estradiol formulation, and monthly medication shipment. The model mirrored what companies like Hims and Hers had proven in adjacent categories: remove the in-person visit friction, price aggressively, and capture a historically underserved population.

The North American Menopause Society (NAMS) 2023 Hormone Therapy Position Statement confirms that hormone therapy remains the most effective treatment for vasomotor symptoms of menopause and that for women under 60 or within 10 years of menopause onset, the benefit-risk ratio is favorable for most women [1]. That clinical backing gave direct-to-consumer HRT platforms a defensible product category.

Mid-Cycle Price Increases (2022 to 2023)

By 2022, Alloy had introduced tiered pricing. Patients on oral estradiol or a basic estradiol patch paid roughly $59, $69/month. Patients requesting compounded estradiol cream or combination estrogen-progesterone protocols moved to a higher tier priced around $75, $85/month. The price differential reflected compounding pharmacy costs rather than clinician time, since the consultation model remained asynchronous for most patients.

Progesterone is required for any woman with an intact uterus who takes estrogen, per the FDA prescribing information for estradiol products [2]. Adding micronized progesterone (Prometrium or generic) pushed the monthly total higher, though Alloy bundled it rather than billing separately, which was a pricing advantage over fragmented pharmacy purchasing.

2024 Pricing: Where Things Stand

As of mid-2024, Alloy's published pricing sits at:

• Estradiol patch or pill (standard tier): $75/month
• Compounded estradiol cream or gel: $85, $99/month
• Combined estrogen + progesterone protocol: $90, $99/month
• Add-on testosterone cream (off-label): additional $30, $45/month

These figures represent a 50% to 100% increase from the 2019 launch price. The company has not published a formal explanation for the increases. Consumer forum posts on Reddit (r/Menopause) and complaint threads on the Better Business Bureau website cite the price changes as a source of friction, particularly for patients who enrolled expecting stable subscription pricing.

Is Alloy Legit? Licensing, Credentials, and Regulatory Standing

Alloy is a legitimate telehealth operation in the sense that it employs licensed physicians, prescribes FDA-approved medications, and operates within U.S. State telehealth frameworks. "legitimate" is not the same as "above reproach," and a full picture requires looking at multiple data sources.

Prescriber and Pharmacy Verification

Alloy's clinicians are licensed in the states where they practice. Patients can verify prescriber licensure through their state's medical board license lookup tool. The FDA's BeSafeRx program advises consumers to confirm any online pharmacy requires a valid prescription and is licensed by their state pharmacy board [3]. Alloy does require a clinician-generated prescription for all medications, which satisfies that threshold.

Compounded medications, however, occupy a different regulatory space. The FDA does not approve compounded drugs for safety and efficacy the way it approves commercially manufactured products [4]. Compounded estradiol creams and gels prescribed through Alloy are mixed by 503A compounding pharmacies, which are regulated by state boards rather than pre-market FDA review. Patients should ask which compounding pharmacy Alloy uses and verify that pharmacy's state licensure independently.

BBB Profile and Consumer Complaints

The Better Business Bureau (BBB) profile for Alloy shows the company is not BBB-accredited as of mid-2024. Consumer complaints filed with the BBB cluster around three themes: unexpected billing after cancellation, difficulty reaching customer support, and delays in prescription renewals. These are operational complaints, not safety complaints, but they are worth noting for anyone managing a chronic condition that requires uninterrupted medication supply.

The FTC's guidance on subscription billing requires clear disclosure of recurring charges and a simple cancellation mechanism [5]. Multiple Alloy BBB complaints allege that cancellation was not as simple as advertised, a pattern the FTC has targeted across the subscription telehealth industry.

LegitScript Status

LegitScript, which certifies online pharmacies and telehealth providers, does not list Alloy as a verified platform as of this review. LegitScript certification is voluntary, so absence of certification does not indicate illegal operation. It does mean patients cannot rely on LegitScript's ongoing monitoring as a quality signal for this provider.

How Alloy's Pricing Compares to Clinical Evidence and Alternatives

Menopause hormone therapy is among the best-studied interventions in women's health. The clinical case for appropriate HRT is strong, and the cost-effectiveness argument for telehealth delivery is also strong. The question is whether Alloy's current price point reflects fair value.

The Clinical Baseline

The SWAN study, a longitudinal cohort following 3,302 women through the menopausal transition, documented that moderate-to-severe vasomotor symptoms affect roughly 45 to 55% of perimenopausal women and persist for a median of 7.4 years [6]. That duration means most women are looking at multi-year treatment, which makes cumulative pricing highly relevant.

A 2022 analysis published in Menopause (the journal of NAMS) found that untreated vasomotor symptoms are associated with reduced work productivity, sleep disruption, and increased healthcare utilization, with estimated annual productivity losses of $1,352 per affected woman [7]. Against that backdrop, $75, $99/month for effective HRT may represent good value, provided the medication is appropriate and well-managed.

The NAMS 2023 position statement is direct: "Hormone therapy is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture" [1]. The strength of that statement supports the clinical model Alloy is built on.

Competitor Pricing Benchmarks

Direct comparison requires care because formularies differ. As of mid-2024:

• Midi Health: $50/month subscription, with medication costs separate (typically $20, $80/month at pharmacy depending on insurance)
• Gennev: No longer offers prescriptions directly; refers to Unified Women's Healthcare network
• Evernow: $99/month all-in for most protocols
• Wisp: Per-visit model at $25, $85/visit, plus pharmacy costs
• Traditional OB/GYN cash pay: $150, $300/visit plus pharmacy costs

At $75, $99/month all-in, Alloy sits in the mid-to-upper range of direct-to-consumer menopause telehealth. The pricing is not predatory by market standards, but the 50 to 100% increase since 2019 outpaces both general medical inflation (roughly 4 to 6% annually per CMS National Health Expenditure data) [8] and CPI inflation over the same period.

Cost Trajectory Projection

If Alloy maintains a 10% annual price increase, the $75/month standard tier would reach approximately $110/month by 2027. Women who enrolled in 2019 at $49/month and remain subscribers would be paying more than double their original rate within eight years. No telehealth subscription in this category has published a price-lock guarantee, and Alloy is no exception.

What Medications Alloy Prescribes: FDA Status and Dosing

Understanding what you are buying matters as much as what you are paying. Alloy prescribes both FDA-approved commercially manufactured products and compounded alternatives.

FDA-Approved Options in the Formulary

Standard Alloy protocols typically include:

• Estradiol transdermal patch (0.025 to 0.1 mg/day): FDA-approved; branded products include Vivelle-Dot and Climara; generics available [2]
• Oral estradiol (0.5 to 2 mg/day): FDA-approved; generic widely available
• Micronized progesterone (100 to 200 mg/day): FDA-approved as Prometrium; required for women with an intact uterus [9]
• Estradiol vaginal cream (0.5 to 4 g/application): FDA-approved; Estrace and generics

The FDA's MedWatch database provides safety reporting for all approved products if patients experience adverse effects [10].

Compounded Formulations

Alloy also offers compounded estradiol creams and combination products not available as FDA-approved commercial products. The FDA has stated clearly that compounded hormone preparations are not tested for safety, purity, potency, or efficacy [4]. For patients who cannot tolerate commercially available formulations, compounding may be medically appropriate. For patients who simply prefer a cream over a patch, the risk-benefit calculation is less obvious.

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy states: "We recommend against the use of compounded bioidentical hormones due to the lack of evidence for safety or efficacy and the risk of under- or over-dosing" [11]. That recommendation remains the professional society position, though many clinicians and patients disagree in practice.

Alloy Complaints: Patterns and What They Mean

Consumer complaints about Alloy are real and worth examining systematically rather than dismissing.

Billing and Cancellation

The most common complaint category involves charges after cancellation attempts. Several BBB complaints describe patients who cancelled online and continued to be billed. This is a compliance issue under FTC regulations rather than a clinical safety issue, but it affects patient trust and financial harm [5].

Prescription Delays

A second complaint cluster involves gaps in medication supply during prescription renewals. For women taking estrogen and progesterone continuously, a two-to-four-week gap is not merely inconvenient. Abrupt discontinuation of hormone therapy can trigger rebound vasomotor symptoms. The NIH MedlinePlus guidance on HRT advises patients to work with clinicians to avoid abrupt discontinuation [12].

Clinical Follow-Up Quality

Some patients report receiving prescriptions with minimal clinical follow-up after the initial consultation. The NAMS 2023 position statement recommends annual re-evaluation of hormone therapy continuation, including breast cancer risk assessment, cardiovascular risk, and symptom review [1]. Asynchronous telehealth models can make that annual evaluation feel perfunctory. Patients should confirm that their Alloy clinician conducts a documented annual review.

How to File a Formal Complaint

Patients with unresolved billing or clinical complaints have several formal channels:

1. BBB complaint: bbb.org for consumer dispute resolution
2. FTC complaint: reportfraud.ftc.gov for billing and subscription practices
3. State medical board: For clinical care concerns involving the prescribing clinician
4. FDA MedWatch: For adverse drug events or suspected product quality issues [10]

Interpreting the Price Trajectory: Value Assessment

The central question for any prospective Alloy patient is whether $75, $99/month represents fair value for medically supervised menopause HRT. The answer depends on several factors.

When Alloy May Offer Good Value

For women who lack insurance coverage for menopause care, have difficulty accessing a local menopause specialist, or have been dismissed by primary care providers (a documented phenomenon: a 2019 survey in Menopause found that 73% of women felt their menopause symptoms were inadequately addressed by their healthcare provider) [13], Alloy's telehealth model provides genuine access improvement.

The CDC data on menopause indicates that approximately 1.3 million U.S. Women reach menopause each year [14]. A substantial proportion have no menopause-competent clinician within reasonable geographic reach. For those patients, paying $75, $99/month for competent remote HRT management is clinically and financially reasonable.

When the Price Is Hard to Justify

For women who have prescription drug coverage, a local OB/GYN, or access to a certified menopause practitioner (NAMS maintains a Menopause Practitioner Locator searchable by zip code), Alloy's current price point may exceed the cost of traditional care with superior follow-up continuity [1].

Generic oral estradiol retails for under $15/month at major pharmacy chains without insurance. Micronized progesterone generic runs $20, $40/month. A patient with a local prescriber could manage both for $35, $55/month in medications alone, saving $20, $64/month compared to Alloy's current pricing, though that calculation excludes the cost and friction of in-person visits.

Regulatory and Safety Oversight of Telehealth HRT

Alloy operates within the broader telehealth regulatory framework that has evolved rapidly since 2020. The FDA's framework for telehealth-prescribed medications emphasizes that prescriptions must come from licensed practitioners who have established a valid patient-provider relationship [3].

State-by-State Variability

Telehealth practice standards vary by state. Some states require a synchronous video visit before prescribing; others permit asynchronous questionnaire-based prescribing. Alloy's ability to prescribe in a given state depends on whether its clinicians hold licensure there and whether state law permits the async model Alloy uses. Patients in states with stricter telehealth prescribing laws may receive a different care model than patients in permissive states.

The Ryan Haight Act and HRT

The Ryan Haight Online Pharmacy Consumer Protection Act governs online prescribing of controlled substances. Testosterone, which Alloy offers as an off-label add-on, is a Schedule III controlled substance [15]. Prescribing testosterone via telehealth requires compliance with Ryan Haight requirements, including an in-person evaluation in most circumstances, unless the patient qualifies under a DEA-registered telemedicine exception. Patients considering testosterone through Alloy should confirm how their prescribing clinician satisfies this requirement.

The DEA's telemedicine rules, updated in 2023, affect how controlled substances including testosterone may be prescribed via telehealth [15]. The regulations remain in a notice-and-comment period, creating ongoing uncertainty for platforms like Alloy that offer testosterone add-ons.